Zobrazeno 1 - 10
of 84
pro vyhledávání: '"Sagun, Parakh"'
Autor:
Malinda Itchins, BMedSci, M.B.B.S., FRACP, PhD, Shirley Liang, BSc, Chris Brown, MBiostats, BSc, Tristan Barnes, BSc (Med), M.B.B.S., FRACP, Gavin Marx, BSc, M.B.B.S., FRACP, Venessa Chin, M.B.B.S., FRACP, PhD, Steven Kao, BHB, MBChB, PhD, FRACP, Po Yee Yip, MBChB, FRACP, PhD, Antony J. Mersiades, BMedSc, M.B.B.S., FRACP, MMed (Clin. Epi), Adnan Nagrial, M.B.B.S., FRACP, PhD, Victoria Bray, M.B.B.S., FRACP, PhD, Geoffrey Peters, BPharm, M.B.B.S., FRACP, Sagun Parakh, BSc, MBChB, FRACP, PhD, Kavita Garg, PhD, Bob T. Li, MD, PhD, MPH, Matthew McKay, PhD, Kenneth O'Byrne, M.B.B.S., FRACP, FRCPA, MD, Thomas John, M.B.B.S., FRACP, PhD, Anthony J. Gill, MD, FRCPA, Mark P. Molloy, PhD, Benjamin J. Solomon, M.B.B.S., FRACP, PhD, Nick Pavlakis, BSc, M.B.B.S., MMed (Clin. Epi), PhD, FRACP
Publikováno v:
JTO Clinical and Research Reports, Vol 5, Iss 9, Pp 100703- (2024)
Introduction: ALK-positive lung cancers represent a molecularly diverse disease. With drug exposure, driving selection pressure, and resistance pathways, disease relapse will emerge. There is compelling rationale to investigate novel treatment strate
Externí odkaz:
https://doaj.org/article/c4d94b5682fa4f42ad7cf98e2bbfcd9a
Autor:
Lavinia Tan, Chris Brown, Antony Mersiades, Chee Khoon Lee, Thomas John, Steven Kao, Genni Newnham, Kenneth O’Byrne, Sagun Parakh, Victoria Bray, Kevin Jasas, Sonia Yip, Stephen Q. Wong, Sarah Ftouni, Jerick Guinto, Sushma Chandrashekar, Stephen Clarke, Nick Pavlakis, Martin R. Stockler, Sarah-Jane Dawson, Benjamin J. Solomon
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-13 (2024)
Abstract In this phase II, single arm trial (ACTRN12617000720314), we investigate if alternating osimertinib and gefitinib would delay the development of resistance to osimertinib in advanced, non-small cell lung cancer (NSCLC) with the epidermal gro
Externí odkaz:
https://doaj.org/article/2aee772d175142968edb2117d86331be
Autor:
Sagun Parakh, Kathryn Lee, Jeremy Rodrigues, Paul Yates, Polly Hypatia Dufton, Elena Tarasenko, Katrina Midgley, Ray Kelly, Surein Arulananda
Publikováno v:
BMJ Open, Vol 14, Iss 1 (2024)
Introduction Cancer is predominantly a disease of older adults, with an increasing number of cancer diagnoses in individuals aged 65 or older. Multiple geriatric factors have been shown to impact patient outcomes in cancer treatment. However, oncolog
Externí odkaz:
https://doaj.org/article/a187c166cf784616bd6b8f5c03c643e8
Autor:
Yang Wang, M.B.B.S., Jared Mathai, M.B.B.S., Muhammad Alamgeer, M.B.B.S., DMedSci, Sagun Parakh, MbChB., PhD, Eldho Paul, PhD, Paul Mitchell, MbChB., MD, Surein Arulananda, M.B.B.S., PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 4, Iss 8, Pp 100544- (2023)
Introduction: There are no clinically validated prognostic biomarkers in the management of extensive-stage SCLC (ES-SCLC). We explored the association between clinical characteristics and survival outcomes in patients with ES-SCLC treated with chemoi
Externí odkaz:
https://doaj.org/article/19897c683b364ac195d9c8c817d928b9
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
Externí odkaz:
https://doaj.org/article/6f09cf06b05440ab85a986b0c6a2e31f
Autor:
Marliese Alexander, B.Pharm(Hons), MPH, PhD, Joe Wei, MD, Sagun Parakh, MD, Thomas John, MD, Steven Kao, MD, Adnan Nagrial, MD, Samantha Bowyer, MD, Lydia Warburton, MD, Melissa Moore, MD, Brett G.M. Hughes, MD, Timothy D. Clay, MD, Nick Pavlakis, MD, Benjamin J. Solomon, MD, Malinda Itchins, MD
Publikováno v:
JTO Clinical and Research Reports, Vol 4, Iss 4, Pp 100490- (2023)
Introduction: Over the past decade, ALK tyrosine kinase inhibitors have delivered unprecedented survival for individuals with ALK-positive (ALK+) lung cancers. Real-world data enhance the understanding of optimal drug sequencing and expectations for
Externí odkaz:
https://doaj.org/article/62a74cb698b1419b955b790acab4a2a3
Publikováno v:
Exploration of Targeted Anti-tumor Therapy, Vol 3, Iss 2, Pp 252-277 (2022)
The recent approvals for antibody-drug conjugates (ADCs) in multiple malignancies in recent years have fuelled the ongoing development of this class of drugs. These novel agents combine the benefits of high specific targeting of oncogenic cell surfac
Externí odkaz:
https://doaj.org/article/3d8ef975652545ae9c093e8ae0cb2d09
Autor:
Christian Wichmann, Sagun Parakh, Gerard G Hanna, Thomas John, Jason Callahan, Benjamin Blyth, Michael MacManus, Daniel Steinfort, Andrew M Scott, Lisa Devereux, Fiona Hegi-Johnson, Stacey E Rudd, Tim Akhurst, Peter Roselt, Jenny Trinh, Paul S Donnelly, Rod Hicks, Stephen Fox, Kate Burbury
Publikováno v:
BMJ Open, Vol 12, Iss 11 (2022)
Background ImmunoPET is a multicentre, single arm, phase 0–1 study that aims to establish if 89Zr-durvalumab PET/CT can be used to interrogate the expression of PD-L1 in larger, multicentre clinical trials.Methods The phase 0 study recruited 5 PD-L
Externí odkaz:
https://doaj.org/article/3ec7e11a980b4b738c6b1a546c955538
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
Glioblastoma (GBM) is an aggressive and fatal malignancy that despite decades of trials has limited therapeutic options. Antibody drug conjugates (ADCs) are composed of a monoclonal antibody which specifically recognizes a cellular surface antigen li
Externí odkaz:
https://doaj.org/article/75bd5259ae494948a7493d5c5e2d644f
Autor:
Sagun Parakh, Ashan Musafer, Sabrina Paessler, Tom Witkowski, Connie S. N. Li Wai Suen, Candani S. A. Tutuka, Matteo S. Carlino, Alexander M. Menzies, Richard A. Scolyer, Jonathan Cebon, Alexander Dobrovic, Georgina V. Long, Oliver Klein, Andreas Behren
Publikováno v:
Frontiers in Immunology, Vol 12 (2021)
A significant number of patients (pts) with metastatic melanoma do not respond to anti-programmed cell death 1 (PD1) therapies. Identifying predictive biomarkers therefore remains an urgent need. We retrospectively analyzed plasma DNA of pts with adv
Externí odkaz:
https://doaj.org/article/60fdb249cd3241e8afe688013434c093